Screening for prostate cancer
173 results
28 - 127
Ask-tell-ask approach to discussing prostate cancer screening- The full truth about prostate cancer screening is suppressed again (ERSPC)
- Prostate cancer screening increases harm risk without decreasing mortality
- Have the USPSTF recommendations against screening caused more aggressive prostate cancer?
- Prostate cancer screening: no mortality benefit after 15 years of follow-up (PLCO)
- Prostate cancer screening: no mortality benefit after 13 years of follow-up (PLCO)
- MA: Low-quality evidence finds DRE screening for prostate cancer inaccurate
- USPSTF 2018 recommends counseling 55 to 69-year-old men on benefits and harms of prostate cancer screening (C recommendation)
- Need to screen 1055 and treat 37 to prevent one prostate CA death over 11 years (ERSPC)
5‐alpha‐reductase inhibitors for prostate cancer prevention- Better estimate of prostate cancer risk based on the number of close relatives with prostate cancer and their age at diagnosis
- PSA screening does not reduce mortality from prostate CA (PLCO)
Prostate cancer - Population screening for cancer
- PSA screening does not decrease mortality
- Low-intensity PSA-based screening does not reduce mortality, but leads to overdiagnosis and potential harm
- Impact of PSA screening on quality of life
- ACP: Discuss prostate screening with men 50-69 years old
- Prediction model can decrease prostate biopsies in men with abnormal PSA
- PSA screening has marginal effect on mortality in European study (ERSPC)
- Modelling study shows less-intense screening is okay for men with low baseline PSA levels
- Five-alpha-reductase inhibitors for prostate cancer prevention
- Observation = radical prostatectomy for most pts with localized prostate cancer (PIVOT)
- PSA plus MRI-guided biopsy reduces the detection of clinically insignificant prostate cancers more than systematic biopsy
- Radical prostatectomy versus watchful waiting for newly diagnosed prostate cancer
- Screening for ovarian cancer with CA-125/ultrasound algorithm does not reduce mortality (UKCTOCS)
- Screening CA-125 and transvaginal ultrasound does not reduce ovarian cancer mortality
- Prostatectomy reduces mortality compared with no surveillance in men with T2 cancer who presented with symptoms
- USPSTF: No PSA screening in men 75 years and older
- For men with PSA > 3.0, limiting biopsy to lesions seen on MRI appears to be safe
- Benign prostatic hyperplasia
- Annual screening chest x-ray does not reduce lung cancer mortality
- Treatment for symptom-detected early prostate CA effective in pts younger than 65
- High false positive rate in repeated, multimodal screening for cancers (PLCO)